Case Report: Comparison different response after neoadjuvant chemotherapy of the breast with cell-in-cell-report of two cases

病例报告:两例乳腺癌新辅助化疗后细胞间反应的比较及细胞内细胞学报告

阅读:1

Abstract

Neoadjuvant chemotherapy (NACT) is commonly applied in human epidermal growth factor receptor 2 (HER2)-positive breast cancer to reduce tumor size and increase the likelihood of breast-conserving surgery. However, predictive markers of response remain limited. We report two cases of HER2-positive breast cancer with divergent responses to NACT, highlighting the dynamics of cell-in-cell structures (CICs). Both patients initially presented with palpable breast masses and biopsy-confirmed HER2-positive invasive carcinoma with frequent CICs. After NACT, one patient achieved a favorable pathological response, accompanied by a reduction in CICs frequency. In contrast, the other patient showed limited response, with persistent complex CICs, which led to an adjustment of the adjuvant regimen. These observations suggest that dynamic cell-in-cell (CIC) patterns may reflect heterogeneous tumor responses to NACT, providing insights for individualized treatment planning.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。